Free Trial
ETR:MDG1

Medigene (MDG1) Stock Price, News & Analysis

€1.18
+0.02 (+1.72%)
(As of 07/16/2024 ET)
Today's Range
€1.16
€1.20
50-Day Range
€1.12
€1.53
52-Week Range
€1.19
€2.90
Volume
10,415 shs
Average Volume
306,207 shs
Market Capitalization
$34.79 million
P/E Ratio
N/A
Dividend Yield
1.31%
Price Target
N/A
MDG1 stock logo

About Medigene Stock (ETR:MDG1)

Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company's end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer. It also focuses on dendritic cell vaccines. Medigene AG has a strategic partnership with BioNTech to develop TCRbased immunotherapies against cancer; and 2seventy bio, Inc. for the development of TCR immunotherapies, as well as a collaboration agreement with National Cancer Institute to evaluate the potential of T cell receptors to be used in new cell constructs for the treatment of solid tumors. It has operations in Germany, the United States, and Asia. The company was founded in 1994 and is headquartered in Munich, Germany.

MDG1 Stock Price History

MDG1 Stock News Headlines

I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
I’m giving you the name of this investment for free
What people don’t know is that Roivant is capitalizing on a wealth secret that goes back over a century. There are a few other public companies who are as well. Only you don’t know it… because it’s not something they openly talk about. That’s why I made this presentation. I want to expose you to a wealth-building secret that you deserve to benefit from.
Medigene to Present at Upcoming Scientific Conferences
PTA-News: Medigene AG: Medigene AG gibt -2-
See More Headlines
Receive MDG1 Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medigene and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
76
Year Founded
N/A

Profitability

Net Income
$-16,180,000.00
Net Margins
-268.10%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.03 million
Cash Flow
€0.86 per share
Book Value
€0.86 per share

Miscellaneous

Free Float
N/A
Market Cap
$34.79 million
Optionable
Not Optionable
Beta
0.91
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Selwyn Ho MB BS (Age 53)
    MBBS, CEO & Member of Executive Management Board
    Comp: $384.47k
  • Dr. Dolores J. Schendel
    Chief Scientific Officer, Member of Executive Management Board and Head of Research & Development
  • Dr. Ernst-Ludwig Winnacker (Age 83)
    Co-Founder & Chairman Scientific Advisory Board
    Comp: $20k
  • Dr. Birger Kohlert
    Chief Financial Officer
  • Pamela Keck
    Vice President of Investor Relations & Corporate Communications
  • Dr. Kirsty Crame M.D.
    VP and Head of Clinical Research & Development

MDG1 Stock Analysis - Frequently Asked Questions

How have MDG1 shares performed this year?

Medigene's stock was trading at €1.53 at the beginning of 2024. Since then, MDG1 shares have decreased by 22.6% and is now trading at €1.18.
View the best growth stocks for 2024 here
.

What other stocks do shareholders of Medigene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Medigene investors own include Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Arbutus Biopharma (ABUS), Aurora Cannabis (ACBFF), AcelRx Pharmaceuticals (ACRX), Aldeyra Therapeutics (ALDX) and

This page (ETR:MDG1) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners